- Eurepa V 0.5/0.3 mg Tablet effectively lowers postprandial blood glucose levels.
- This medication is used in the management of Type 2 diabetes mellitus.
- Eurepa V 0.5/0.3 mg Tablet helps prevent complications associated with diabetes.
- It combines the benefits of Repaglinide and Voglibose for enhanced glycemic control.
- The formulation supports better blood sugar management when used alongside diet and exercise.
- Eurepa V 0.5/0.3 mg Tablet is beneficial for patients who experience high blood sugar spikes after meals.
- This therapy can reduce the risk of cardiovascular complications related to diabetes.
- Eurepa V 0.5/0.3 mg Tablet aids in improving overall metabolic activity in diabetic patients.
Eurepa V 0.5/0.3 mg Tablet - Strip of 10
Prescription Required
Compositions : Voglibose 0.3mg + Repaglinide 0.5mg
₹146.40
(Incl. GST)
MRP :
(Incl. GST)
MRP :
In stock
Delivery within 2 to 7 Working Days
Manufacture/Marketer: Torrent Pharmaceuticals Ltd
Door Step Delivery
Quick and Secure
No Hidden Charges
Pay only what's shown
18K Pincodes Served
With Trust & Reliability
Description
Eurepa V 0.5/0.3 mg Tablet is a specialized pharmaceutical formulation designed for the management of Type 2 diabetes mellitus. This medication combines two active ingredients, Repaglinide and Voglibose, which work synergistically to help control blood sugar levels effectively. The key composition of Eurepa V 0.5/0.3 mg Tablet includes 0.5 mg of Repaglinide, a rapid-acting insulin secretagogue, and 0.3 mg of Voglibose, an alpha-glucosidase inhibitor. Together, these components target different mechanisms involved in glucose metabolism, making Eurepa V 0.5/0.3 mg Tablet a valuable option for patients struggling with diabetes management. The primary purpose of Eurepa V 0.5/0.3 mg Tablet is to lower postprandial blood glucose levels, thereby reducing the risk of hyperglycemia after meals. As part of the therapeutic category of antidiabetic agents, Eurepa V 0.5/0.3 mg Tablet is particularly beneficial for individuals who require additional glycemic control alongside diet and exercise. By utilizing this combination therapy, patients can achieve better overall glycemic control and improve their quality of life. The unique formulation of Eurepa V 0.5/0.3 mg Tablet not only aids in managing blood sugar levels but also helps prevent complications associated with diabetes, such as cardiovascular issues and neuropathy. With its dual-action mechanism, Eurepa V 0.5/0.3 mg Tablet stands out as an effective treatment option for those diagnosed with Type 2 diabetes mellitus, ensuring that patients can maintain their health and well-being while managing their condition effectively.
Product Details
Uses & Benefits
How Eurepa V 0.5/0.3 mg Tablet works
Eurepa V 0.5/0.3 mg Tablet works through a dual mechanism involving its active ingredients, Repaglinide and Voglibose, to regulate blood sugar levels effectively.
Eurepa V 0.5/0.3 mg Tablet works through a dual mechanism involving its active ingredients, Repaglinide and Voglibose, to regulate blood sugar levels effectively.
- Repaglinide: Stimulates insulin secretion from the pancreas in response to meals, helping to lower blood glucose levels quickly.
- Voglibose: Delays carbohydrate absorption in the intestines by inhibiting alpha-glucosidase, which helps prevent post-meal blood sugar spikes.
- The combination enhances glycemic control more effectively than either component alone.
- By addressing both insulin secretion and carbohydrate absorption, Eurepa V 0.5/0.3 mg Tablet provides comprehensive management of Type 2 diabetes.
- This synergistic action helps maintain stable blood glucose levels throughout the day.
How to use Eurepa V 0.5/0.3 mg Tablet
- Eurepa V 0.5/0.3 mg Tablet should be taken approximately 15 minutes before a main meal.
- The recommended dosage is typically one tablet per meal, as prescribed by a healthcare professional.
- Frequency of administration usually involves taking the medication three times daily with meals.
- Duration of treatment with Eurepa V 0.5/0.3 mg Tablet should be determined by a healthcare provider based on individual patient needs.
- Special instructions include monitoring blood glucose levels regularly to avoid hypoglycemia.
Lifestyle Advice
- Maintain a balanced diet rich in whole grains, vegetables, and lean proteins while using Eurepa V 0.5/0.3 mg Tablet.
- Avoid excessive consumption of sugary foods and beverages to help manage blood sugar levels effectively.
- Incorporate regular physical activity into your routine to enhance the effectiveness of Eurepa V 0.5/0.3 mg Tablet.
- Monitor blood glucose levels regularly to ensure they remain within target ranges while on this medication.
- Stay hydrated by drinking plenty of water throughout the day to support overall health and metabolic function.
Safety Advice
Side Effects
Side Effects
- Common side effects of Eurepa V 0.5/0.3 mg Tablet may include diarrhea and abdominal pain.
- Hypoglycemia (low blood sugar) is a potential side effect; symptoms include cold sweats and tremors.
- Upper respiratory tract infections and headaches have also been reported among users.
- Serious side effects may necessitate immediate medical attention if they occur.
Precautions and Warnings
Precautions & Warnings
- Eurepa V 0.5/0.3 mg Tablet should not be used by individuals with known hypersensitivity to its components.
- Patients with severe liver or kidney impairment should consult their doctor before using this medication.
- Alcohol consumption may increase the risk of hypoglycemia when taking Eurepa V 0.5/0.3 mg Tablet.
- Pregnant or breastfeeding women should discuss potential risks with their healthcare provider before starting treatment.
- Driving or operating heavy machinery should be approached with caution due to the risk of hypoglycemia.
FAQs
1. What is Eurepa V 0.5/0.3 mg Tablet used for?
Eurepa V 0.5/0.3 mg Tablet is primarily used for managing Type 2 diabetes mellitus by controlling blood sugar levels.
2. How should I take Eurepa V 0.5/0.3 mg Tablet?
Eurepa V 0.5/0.3 mg Tablet should be taken about 15 minutes before meals, typically three times a day as prescribed.
3. What are the common side effects of Eurepa V 0.5/0.3 mg Tablet?
Common side effects include diarrhea, abdominal pain, and hypoglycemia, which may require monitoring.
4. Can I drink alcohol while taking Eurepa V 0.5/0.3 mg Tablet?
Alcohol consumption may increase the risk of low blood sugar when using Eurepa V 0.5/0.3 mg Tablet; caution is advised.
5. Who should avoid using Eurepa V 0.5/0.3 mg Tablet?
Individuals with hypersensitivity to its components or severe liver or kidney impairment should avoid using Eurepa V 0.5/0.3 mg Tablet.
6. Is it safe to use Eurepa V 0.5/0.3 mg Tablet during pregnancy?
Pregnant women should consult their healthcare provider before using Eurepa V 0.5/0.3 mg Tablet due to potential risks.
7. How does Eurepa V 0.5/0.3 mg Tablet work?
Eurepa V 0.5/0.3 mg Tablet works by combining Repaglinide and Voglibose to enhance insulin secretion and reduce carbohydrate absorption.
Eurepa V 0.5/0.3 mg Tablet is primarily used for managing Type 2 diabetes mellitus by controlling blood sugar levels.
2. How should I take Eurepa V 0.5/0.3 mg Tablet?
Eurepa V 0.5/0.3 mg Tablet should be taken about 15 minutes before meals, typically three times a day as prescribed.
3. What are the common side effects of Eurepa V 0.5/0.3 mg Tablet?
Common side effects include diarrhea, abdominal pain, and hypoglycemia, which may require monitoring.
4. Can I drink alcohol while taking Eurepa V 0.5/0.3 mg Tablet?
Alcohol consumption may increase the risk of low blood sugar when using Eurepa V 0.5/0.3 mg Tablet; caution is advised.
5. Who should avoid using Eurepa V 0.5/0.3 mg Tablet?
Individuals with hypersensitivity to its components or severe liver or kidney impairment should avoid using Eurepa V 0.5/0.3 mg Tablet.
6. Is it safe to use Eurepa V 0.5/0.3 mg Tablet during pregnancy?
Pregnant women should consult their healthcare provider before using Eurepa V 0.5/0.3 mg Tablet due to potential risks.
7. How does Eurepa V 0.5/0.3 mg Tablet work?
Eurepa V 0.5/0.3 mg Tablet works by combining Repaglinide and Voglibose to enhance insulin secretion and reduce carbohydrate absorption.
Instructions
Directions for Use
Use only as prescribed by your physician.
Storage and Disposal
- Store below 25°C in a dry place, protected from light and moisture.
- Keep out of reach of children.
- Dispose unused or expired tablets as per local regulations or consult a pharmacist for safe disposal.
More Information
| SKU | 443022 |
|---|---|
| Country of Manufacture | India |
| Manufacturer Address | Torrent Pharmaceuticals Ltd |
| Return/Buy Back policy | Non-returnable |
| Prescription Required | Yes |
| Storage |
|
| Seller | Kogland Commerce Pvt Ltd (TN) |
Eurepa V 0.5/0.3 mg Tablet is a specialized pharmaceutical formulation designed for the management of Type 2 diabetes mellitus. This medication combines two active ingredients, Repaglinide and Voglibose, which work synergistically to help control blood sugar levels effectively. The key composition of Eurepa V 0.5/0.3 mg Tablet includes 0.5 mg of Repaglinide, a rapid-acting insulin secretagogue, and 0.3 mg of Voglibose, an alpha-glucosidase inhibitor. Together, these components target different mechanisms involved in glucose metabolism, making Eurepa V 0.5/0.3 mg Tablet a valuable option for patients struggling with diabetes management. The primary purpose of Eurepa V 0.5/0.3 mg Tablet is to lower postprandial blood glucose levels, thereby reducing the risk of hyperglycemia after meals. As part of the therapeutic category of antidiabetic agents, Eurepa V 0.5/0.3 mg Tablet is particularly beneficial for individuals who require additional glycemic control alongside diet and exercise. By utilizing this combination therapy, patients can achieve better overall glycemic control and improve their quality of life. The unique formulation of Eurepa V 0.5/0.3 mg Tablet not only aids in managing blood sugar levels but also helps prevent complications associated with diabetes, such as cardiovascular issues and neuropathy. With its dual-action mechanism, Eurepa V 0.5/0.3 mg Tablet stands out as an effective treatment option for those diagnosed with Type 2 diabetes mellitus, ensuring that patients can maintain their health and well-being while managing their condition effectively.
Uses & Benefits
- Eurepa V 0.5/0.3 mg Tablet effectively lowers postprandial blood glucose levels.
- This medication is used in the management of Type 2 diabetes mellitus.
- Eurepa V 0.5/0.3 mg Tablet helps prevent complications associated with diabetes.
- It combines the benefits of Repaglinide and Voglibose for enhanced glycemic control.
- The formulation supports better blood sugar management when used alongside diet and exercise.
- Eurepa V 0.5/0.3 mg Tablet is beneficial for patients who experience high blood sugar spikes after meals.
- This therapy can reduce the risk of cardiovascular complications related to diabetes.
- Eurepa V 0.5/0.3 mg Tablet aids in improving overall metabolic activity in diabetic patients.
How Eurepa V 0.5/0.3 mg Tablet works
Eurepa V 0.5/0.3 mg Tablet works through a dual mechanism involving its active ingredients, Repaglinide and Voglibose, to regulate blood sugar levels effectively.
Eurepa V 0.5/0.3 mg Tablet works through a dual mechanism involving its active ingredients, Repaglinide and Voglibose, to regulate blood sugar levels effectively.
- Repaglinide: Stimulates insulin secretion from the pancreas in response to meals, helping to lower blood glucose levels quickly.
- Voglibose: Delays carbohydrate absorption in the intestines by inhibiting alpha-glucosidase, which helps prevent post-meal blood sugar spikes.
- The combination enhances glycemic control more effectively than either component alone.
- By addressing both insulin secretion and carbohydrate absorption, Eurepa V 0.5/0.3 mg Tablet provides comprehensive management of Type 2 diabetes.
- This synergistic action helps maintain stable blood glucose levels throughout the day.
How to use Eurepa V 0.5/0.3 mg Tablet
- Eurepa V 0.5/0.3 mg Tablet should be taken approximately 15 minutes before a main meal.
- The recommended dosage is typically one tablet per meal, as prescribed by a healthcare professional.
- Frequency of administration usually involves taking the medication three times daily with meals.
- Duration of treatment with Eurepa V 0.5/0.3 mg Tablet should be determined by a healthcare provider based on individual patient needs.
- Special instructions include monitoring blood glucose levels regularly to avoid hypoglycemia.
Lifestyle Advice
- Maintain a balanced diet rich in whole grains, vegetables, and lean proteins while using Eurepa V 0.5/0.3 mg Tablet.
- Avoid excessive consumption of sugary foods and beverages to help manage blood sugar levels effectively.
- Incorporate regular physical activity into your routine to enhance the effectiveness of Eurepa V 0.5/0.3 mg Tablet.
- Monitor blood glucose levels regularly to ensure they remain within target ranges while on this medication.
- Stay hydrated by drinking plenty of water throughout the day to support overall health and metabolic function.
Side Effects
Side Effects
- Common side effects of Eurepa V 0.5/0.3 mg Tablet may include diarrhea and abdominal pain.
- Hypoglycemia (low blood sugar) is a potential side effect; symptoms include cold sweats and tremors.
- Upper respiratory tract infections and headaches have also been reported among users.
- Serious side effects may necessitate immediate medical attention if they occur.
Precautions and Warnings
Precautions & Warnings
- Eurepa V 0.5/0.3 mg Tablet should not be used by individuals with known hypersensitivity to its components.
- Patients with severe liver or kidney impairment should consult their doctor before using this medication.
- Alcohol consumption may increase the risk of hypoglycemia when taking Eurepa V 0.5/0.3 mg Tablet.
- Pregnant or breastfeeding women should discuss potential risks with their healthcare provider before starting treatment.
- Driving or operating heavy machinery should be approached with caution due to the risk of hypoglycemia.
1. What is Eurepa V 0.5/0.3 mg Tablet used for?
Eurepa V 0.5/0.3 mg Tablet is primarily used for managing Type 2 diabetes mellitus by controlling blood sugar levels.
2. How should I take Eurepa V 0.5/0.3 mg Tablet?
Eurepa V 0.5/0.3 mg Tablet should be taken about 15 minutes before meals, typically three times a day as prescribed.
3. What are the common side effects of Eurepa V 0.5/0.3 mg Tablet?
Common side effects include diarrhea, abdominal pain, and hypoglycemia, which may require monitoring.
4. Can I drink alcohol while taking Eurepa V 0.5/0.3 mg Tablet?
Alcohol consumption may increase the risk of low blood sugar when using Eurepa V 0.5/0.3 mg Tablet; caution is advised.
5. Who should avoid using Eurepa V 0.5/0.3 mg Tablet?
Individuals with hypersensitivity to its components or severe liver or kidney impairment should avoid using Eurepa V 0.5/0.3 mg Tablet.
6. Is it safe to use Eurepa V 0.5/0.3 mg Tablet during pregnancy?
Pregnant women should consult their healthcare provider before using Eurepa V 0.5/0.3 mg Tablet due to potential risks.
7. How does Eurepa V 0.5/0.3 mg Tablet work?
Eurepa V 0.5/0.3 mg Tablet works by combining Repaglinide and Voglibose to enhance insulin secretion and reduce carbohydrate absorption.
Eurepa V 0.5/0.3 mg Tablet is primarily used for managing Type 2 diabetes mellitus by controlling blood sugar levels.
2. How should I take Eurepa V 0.5/0.3 mg Tablet?
Eurepa V 0.5/0.3 mg Tablet should be taken about 15 minutes before meals, typically three times a day as prescribed.
3. What are the common side effects of Eurepa V 0.5/0.3 mg Tablet?
Common side effects include diarrhea, abdominal pain, and hypoglycemia, which may require monitoring.
4. Can I drink alcohol while taking Eurepa V 0.5/0.3 mg Tablet?
Alcohol consumption may increase the risk of low blood sugar when using Eurepa V 0.5/0.3 mg Tablet; caution is advised.
5. Who should avoid using Eurepa V 0.5/0.3 mg Tablet?
Individuals with hypersensitivity to its components or severe liver or kidney impairment should avoid using Eurepa V 0.5/0.3 mg Tablet.
6. Is it safe to use Eurepa V 0.5/0.3 mg Tablet during pregnancy?
Pregnant women should consult their healthcare provider before using Eurepa V 0.5/0.3 mg Tablet due to potential risks.
7. How does Eurepa V 0.5/0.3 mg Tablet work?
Eurepa V 0.5/0.3 mg Tablet works by combining Repaglinide and Voglibose to enhance insulin secretion and reduce carbohydrate absorption.
Directions for Use
Use only as prescribed by your physician.
Storage and Disposal
- Store below 25°C in a dry place, protected from light and moisture.
- Keep out of reach of children.
- Dispose unused or expired tablets as per local regulations or consult a pharmacist for safe disposal.
| SKU | 443022 |
|---|---|
| Country of Manufacture | India |
| Manufacturer Address | Torrent Pharmaceuticals Ltd |
| Return/Buy Back policy | Non-returnable |
| Prescription Required | Yes |
| Storage |
|
| Seller | Kogland Commerce Pvt Ltd (TN) |
Door Step Delivery
Quick and Secure
No Hidden Charges
Pay only what's shown
18K Pincodes Served
With Trust & Reliability
Customer Reviews
No reviews yet
Be the first to share your thoughts. Honest feedback helps other shoppers and us serve you better.
Write Your Own Review
Only registered users can write reviews. Please Sign in or create an account